Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants

Documenti analoghi

• Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention
  di: Stephanie C. M. Wuyts, et al.
  Pubblicazione: (2025)
• Appropriateness of direct oral anticoagulant prescribing in older subjects with atrial fibrillation discharged from acute medical wards
  di: Antonio De Vincentis, et al.
  Pubblicazione: (2024)
• Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer
  di: Ana Rita Simoes, et al.
  Pubblicazione: (2025)
• Association between oral anticoagulant therapy and in‐hospital complications and mortality
  di: Juliana Lagrave, et al.
  Pubblicazione: (2025)
• Assessing the applicability of the DOAC, HAS‐BLED and ORBIT risk scores in Chinese patients on non‐vitamin K antagonist oral anticoagulants
  di: Miao Fan, et al.
  Pubblicazione: (2025)